Natixis Advisors LLC Has $17.12 Million Stock Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Natixis Advisors LLC increased its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 29.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 209,175 shares of the company's stock after buying an additional 48,009 shares during the period. Natixis Advisors LLC owned 0.24% of HealthEquity worth $17,122,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in HealthEquity by 1.7% in the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company's stock valued at $715,783,000 after acquiring an additional 149,133 shares during the last quarter. Vaughan Nelson Investment Management L.P. boosted its position in HealthEquity by 1.8% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 616,860 shares of the company's stock valued at $53,173,000 after buying an additional 11,150 shares during the period. Oppenheimer Asset Management Inc. boosted its position in HealthEquity by 29.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company's stock valued at $5,535,000 after buying an additional 14,573 shares during the period. Diversify Wealth Management LLC purchased a new stake in shares of HealthEquity in the 2nd quarter worth about $8,182,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of HealthEquity in the 3rd quarter worth about $638,000. 99.55% of the stock is owned by institutional investors.

HealthEquity Trading Up 0.1 %

NASDAQ:HQY traded up $0.12 on Wednesday, reaching $102.79. 309,609 shares of the company's stock were exchanged, compared to its average volume of 623,524. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $103.16. The firm has a market capitalization of $8.98 billion, a price-to-earnings ratio of 85.22, a price-to-earnings-growth ratio of 1.55 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The business has a fifty day moving average of $86.10 and a 200-day moving average of $81.42.

HealthEquity (NASDAQ:HQY - Get Free Report) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.16. The company had revenue of $299.93 million during the quarter, compared to analysts' expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. As a group, analysts expect that HealthEquity, Inc. will post 2.27 earnings per share for the current year.

Insider Activity at HealthEquity

In other HealthEquity news, Director Frank Corvino sold 1,039 shares of HealthEquity stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the sale, the director now owns 3,784 shares of the company's stock, valued at $363,642.40. The trade was a 21.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the business's stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the sale, the director now directly owns 54,719 shares in the company, valued at $4,540,582.62. This trade represents a 13.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,536 shares of company stock valued at $884,517 over the last quarter. Insiders own 2.20% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on HQY shares. Bank of America increased their price target on shares of HealthEquity from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. JMP Securities reaffirmed a "market outperform" rating and set a $105.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. The Goldman Sachs Group started coverage on shares of HealthEquity in a report on Friday, November 15th. They issued a "neutral" rating and a $108.00 price objective on the stock. BTIG Research lifted their price target on shares of HealthEquity from $110.00 to $130.00 and gave the company a "buy" rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $92.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $107.23.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.